Dr. Martens (LON:DOCS) Receives “Sector perform” Rating from Royal Bank Of Canada

Dr. Martens (LON:DOCS)‘s stock had its “sector perform” rating reaffirmed by equities researchers at Royal Bank Of Canada in a report released on Tuesday,Digital Look reports. They currently have a GBX 100 price objective on the stock. Royal Bank Of Canada’s target price points to a potential upside of 49.81% from the company’s current price.

Several other equities research analysts have also weighed in on DOCS. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research note on Tuesday, January 27th. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Dr. Martens has an average rating of “Moderate Buy” and a consensus price target of GBX 100.

Dr. Martens Stock Performance

LON:DOCS opened at GBX 66.75 on Tuesday. The firm has a 50-day moving average of GBX 75.55 and a two-hundred day moving average of GBX 83.06. The stock has a market cap of £645.18 million, a P/E ratio of 39.26, a PEG ratio of 6.40 and a beta of 0.11. Dr. Martens has a 1-year low of GBX 43.02 and a 1-year high of GBX 100.87. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13.

Dr. Martens (LON:DOCS) last issued its earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, research analysts expect that Dr. Martens will post 2.5809394 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Robert Hanson acquired 96,000 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was bought at an average price of GBX 79 per share, for a total transaction of £75,840. Over the last 90 days, insiders have purchased 97,130 shares of company stock valued at $7,673,816. Insiders own 2.79% of the company’s stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.